# Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

> **NCT04047732** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Krystal Biotech, Inc.** · enrollment: 6 (estimated)

## Conditions studied

- TGM-1 Related Autosomal Recessive Congenital Ichthyosis

## Interventions

- **BIOLOGICAL:** KB105

## Key facts

- **NCT ID:** NCT04047732
- **Lead sponsor:** Krystal Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-27
- **Primary completion:** 2022-10
- **Final completion:** 2025-03
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2021-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04047732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04047732, "Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04047732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*